Clay Siegall: Fighting Cancer through Research and Innovation

Dr. Clay B Siegall is widely known for his contributions towards the advancement of the genetics sector. He is the founder and owner of Seattle Genetics. His company deals with the production of antibody medication. His work has earned him worldwide recognition and respect. Aside from his executive position at Seattle Genetics, Clay runs a WordPress blog called Clay Siegall. He posts content on various subjects that his audience can relate to. Most of the content the site is from NPR, which is a reliable news network.

Clay’s recent blog articles include the criticism surrounding the Paris Climate Agreement, President Trump’s decision on the Paris Accord and sustainability. Judging from his blog, Clay Siegall is interested in policies affecting the climate. He is closely following the Paris Climate Agreement, which is currently a hot topic in the United States. Additionally, Mr. Siegall interested in other scientific studies such as astronomy. He posted an article from NPR that discusses a group that is trying to find an “overexcited planet.” Even though the majority of the content is about politics, sports, animal science and agriculture, Clay still posts cancer-related studies.

More about Dr. Clay Siegall

Clay B Siegall has served as the president of Seattle Genetics since the inception of the company. He focuses his studies and works on cancer. Some of the medical solutions offered by his company include antibody conjugates and targeted cancer therapies. Clay started Seattle Genetics to create innovative solutions and carry out rigorous research. His products and studies have helped a lot of patients. In 2011, his firm began producing ADCETRIS, an antibody-drug conjugate. After releasing the drug to the market, Seattle Genetics got the FDA approval.

Under Mr. Siegall’s leadership, the company has partnered with various pharmaceutical brands and acquired some strategic licenses. These licenses have generated more than $350 million in revenue. Seattle Genetics is associated with GlaxoSmithKline, AbbVie, Pfizer, and Genentech. Dr. Clay Siegall has a degree in Zoology. He also holds a Doctorate in Genetics. Siegall began at the National Institute of Health. He has worked with reputable companies, which include Curagen Corporation, Bristol-Myers Squibb, and Med-Immune. Clay has received multiple awards for his work in the cancer research community.

Leave a Reply